SCI-160
Chronic Pain
PreclinicalActive
Key Facts
About SciSparc
SciSparc is a clinical-stage biotech focused on developing optimized cannabinoid-based combination therapies for CNS disorders. Its mission is to create safer, more effective pharmaceutical treatments by synergistically combining cannabinoids with approved drugs. Key achievements include advancing its lead candidate for Tourette syndrome into a Phase IIb trial and securing intellectual property for its platform. The strategy is to de-risk development by repurposing known molecules while building a pipeline anchored in proprietary synergistic combinations.
View full company profileTherapeutic Areas
Other Chronic Pain Drugs
| Drug | Company | Phase |
|---|---|---|
| Injectrode Platform for Chronic Pain | Neuronoff | Pre-clinical |
| Novel PNS System | Nervonik | First-in-Human Completed |
| Pain Pipeline | Centrexion Therapeutics | Clinical Stage |
| High-Definition Spinal Cord Stimulation | Micro-Leads | Unknown |
| Precision Medicine for Pain | MindX Sciences | Commercial |
| Chronic Pain Program | Current Surgical | Research |
| N-19a | Neurocarrus | Pre-clinical |
| Nav1.7 ASO | Quiver Bioscience | Discovery |
| Nav1.8 ASO | Quiver Bioscience | Discovery |
| Dual Nav1.7/1.8 ASO | Quiver Bioscience | Discovery |
| TMS for Chronic Pain | Magstim | Commercial/Clinical Development |
| Orion pain portfolio candidates | Orion | Not Specified / Various |